BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15118478)

  • 1. A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia.
    Citrome L; Tremeau F; Wynn PS; Roy B; Dinakar H
    J Clin Psychopharmacol; 2004 Jun; 24(3):255-9. PubMed ID: 15118478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium.
    Horne RL; Cunanan C
    J Clin Psychopharmacol; 2003 Apr; 23(2):176-81. PubMed ID: 12640219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers.
    Dutta S; Zhang Y; Selness DS; Lee LL; Williams LA; Sommerville KW
    Epilepsy Res; 2002 Mar; 49(1):1-10. PubMed ID: 11948003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-release divalproex sodium for mood stabilization.
    Stoner SC; Dubisar BM; Lea JW; Marken PA; Ramlatchman LV; Reynolds JB
    Pharmacotherapy; 2004 Sep; 24(9):1147-53. PubMed ID: 15460175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study.
    Apostol G; Lewis DW; Laforet GA; Robieson WZ; Fugate JM; Abi-Saab WM; Saltarelli MD
    Headache; 2009 Jan; 49(1):45-53. PubMed ID: 19040679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex.
    Davis LL; Li X; Bartolucci AA; Williford RB; Lowe JS
    J Clin Psychiatry; 2007 Oct; 68(10):1546-51. PubMed ID: 17960970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents.
    Wagner KD; Redden L; Kowatch RA; Wilens TE; Segal S; Chang K; Wozniak P; Vigna NV; Abi-Saab W; Saltarelli M
    J Am Acad Child Adolesc Psychiatry; 2009 May; 48(5):519-532. PubMed ID: 19325497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet.
    Garikipati V; Toops DS; Fang Q
    Curr Med Res Opin; 2008 Jul; 24(7):1869-76. PubMed ID: 18593524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
    Reed RC; Dutta S; Liu W
    Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up.
    McCabe PH; Michel NC; McNew CD; Lehman EB
    Epilepsy Behav; 2006 May; 8(3):601-5. PubMed ID: 16678766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents.
    Apostol G; Pakalnis A; Laforet GA; Robieson WZ; Olson E; Abi-Saab WM; Saltarelli M
    Headache; 2009 Jan; 49(1):36-44. PubMed ID: 19040678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.
    Dutta S; Reed RC
    Clin Drug Investig; 2006; 26(12):681-90. PubMed ID: 17274675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials.
    Smith MC; Centorrino F; Welge JA; Collins MA
    Epilepsy Behav; 2004 Oct; 5(5):746-51. PubMed ID: 15380129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
    Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
    Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overnight versus progressive conversion of multiple daily-dose divalproex to once-daily divalproex extended release: which strategy is better tolerated by adults with intellectual disabilities?
    Hellings JA; Barth FX; Logan M; Cook-Wiens G; Osorio I; Reed RC
    J Clin Psychopharmacol; 2009 Oct; 29(5):492-5. PubMed ID: 19745651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.
    Freitag FG; Collins SD; Carlson HA; Goldstein J; Saper J; Silberstein S; Mathew N; Winner PK; Deaton R; Sommerville K;
    Neurology; 2002 Jun; 58(11):1652-9. PubMed ID: 12058094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study.
    Apostol G; Cady RK; Laforet GA; Robieson WZ; Olson E; Abi-Saab WM; Saltarelli M
    Headache; 2008 Jul; 48(7):1012-25. PubMed ID: 18705027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania.
    Hirschfeld RM; Bowden CL; Vigna NV; Wozniak P; Collins M
    J Clin Psychiatry; 2010 Apr; 71(4):426-32. PubMed ID: 20361904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania.
    Bowden CL; Swann AC; Calabrese JR; Rubenfaer LM; Wozniak PJ; Collins MA; Abi-Saab W; Saltarelli M;
    J Clin Psychiatry; 2006 Oct; 67(10):1501-10. PubMed ID: 17107240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divalproex-ER pharmacokinetics in older children and adolescents.
    Dutta S; Zhang Y; Conway JM; Sallee FR; Biton V; Reed MD; Kearns GL
    Pediatr Neurol; 2004 May; 30(5):330-7. PubMed ID: 15165635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.